Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-centre, Randomised, Double-blind, Placebo-controlled, Multiple-dose Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects

X
Trial Profile

A Single-centre, Randomised, Double-blind, Placebo-controlled, Multiple-dose Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Atherosclerosis; Liver cirrhosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity; Peripheral arterial disorders; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Nov 2020 Results assessing the pharmacokinetics, safety and tolerability of semaglutide in healthy Chinese subjects, published in the Advances in Therapy
    • 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
    • 08 Aug 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top